Liquidity & Technical

Liquidity & Technical

A 5% position is implementable for funds up to roughly $5.7B at a 20% ADV pace, clearing in five trading days — liquidity is not the bottleneck for any institutional sleeve. The tape is constructive on a multi-year basis (5y +236%, 3y +165%, 1y +35%) but has rolled over near-term: price sits 4.7% below the 200-day for the first time since the June 2025 golden cross, RSI is neutral at 47, and the most important feature is whether MACD histogram's recent flip back to positive is a genuine bottom or a counter-trend bounce inside a deeper distribution.

Portfolio implementation verdict

Price snapshot

The one-year tape is still positive but the stock has shed roughly 23% from the 52-week high of $244.80 set within the past twelve months and now sits in the lower half of that range. Realized volatility around 35% is in the lower-half of the 10-year regime — there is no panic in the price action, just drift.

The critical chart — 10-year price with 50/200 SMA

Price is below the 200-day by 4.7% as of the latest close. Read the chart this way: a decade-long secular uptrend (from $28 in 2016 to a $244.80 peak in 2025), interrupted by a clean six-month distribution that now has price flirting with the 200-day support. This is a pullback inside an uptrend, not a regime change — yet.

Relative strength vs benchmarks

In absolute terms, $100 invested three years ago is worth $262 today — a 161% gain that materially outpaces the broad U.S. equity market over the same window. Even after the recent pullback, the three-year line remains in a clear uptrend, with the recent fade only retracing roughly 20% of the prior advance.

Momentum — RSI and MACD

RSI at 47 is neutral — neither overbought nor oversold, and unable to confirm either direction. The MACD histogram has just flipped positive in the last few sessions (+0.64) after running deeply negative for months, but the MACD line remains far below zero (-5.23 vs signal -5.88). The honest read: momentum has bottomed locally, but a single positive histogram print is a setup, not a confirmation. Watch for the MACD line itself to cross above signal (it has) and then climb above zero (it has not).

Volume, volatility, and sponsorship

Volume action is unremarkable — the recent 12 months show daily activity hugging the 50-day moving average with no conviction-trade spikes, which is consistent with a stock that is drifting rather than being actively re-rated. The three lifetime volume events are all from prior cycles and skewed to the downside, including the 31% Q3 2022 earnings collapse that was the single largest negative print of the past decade.

Recent realized volatility of 35% sits between the 10-year 20th percentile (32%) and median (44%) — a calm-to-normal regime. The market is not pricing in stress; it is repricing slowly. That distinction matters: when distribution happens at low realized vol, it tends to extend further than people expect because there is no climactic flush to mark the bottom.

Institutional liquidity panel

This stock is a regular for institutional accounts. Annual share turnover of 341% means the entire float changes hands more than three times each year. Median daily range of 1.55% is modest — not a tight microcap and not a whippy growth name.

A. ADV and turnover strip

B. Fund-capacity table

How much fund AUM can THC support at common position weights, given five trading days to build the position?

A $5.7B-AUM fund can build a 5% position over five trading days at a 20% ADV cap. A more conservative 10% ADV cap halves that — supporting up to a $2.8B fund at a 5% weight. For a $10B-plus shop, the math forces either a smaller weight, a longer build window, or block execution.

C. Liquidation runway

How fast can a sized issuer-level position be exited at constrained participation?

D. Daily-range proxy

Median 60-day daily range is 1.55% — modest. Below the 2% threshold that would flag elevated impact cost. Bid-ask cost is not the binding constraint on size; participation discipline is.

The bottom line: at 20% ADV the largest issuer-level position that clears in five days is roughly 1.0% of market cap ($170M, 908K shares). At a more conservative 10% ADV the limit drops to 0.5% of market cap ($85M). For mainstream long-only and L/S funds, this is a fully tradable name; for very large multi-strategy platforms, the position is sized by participation rate rather than by conviction.

Technical scorecard and stance

Stance: NEUTRAL on the 3-to-6 month horizon, with a constructive structural bias. The multi-year uptrend remains intact (50-day above 200-day, golden cross since June 2025) and the longer absolute return profile is one of the strongest in U.S. health-care services. But the recent six-month tape has been a quiet distribution: price has rolled below both the 50-day and the 200-day, RSI cannot lift above 50, MACD has only just flipped to a hesitant positive histogram, and volume offers no buying climax. Two specific levels frame the next move:

• Above $205 (50-day SMA) — a clean reclaim with the MACD line crossing above zero would confirm the pullback is over and re-engage the multi-year trend. That is the add signal.
• Below $172 (recent support) — a close below this level would mark the death cross as the dominant signal, with a measured next stop near $160 and the 52-week low of $137 in play. That is the trim/exit signal.

Liquidity is not the constraint. A $5.7B-AUM fund can build a 5% position in five trading days at 20% ADV; the binding question for action is the tape, not capacity. Implementation guidance: watchlist for funds under $2B AUM with conviction in the long-term hospital thesis (build slowly into a 50-day reclaim); for size-aware multi-strategy books, wait for the price-vs-200d to flip back positive before sizing up.